Gilead Sciences, Inc. $GILD Shares Sold by Arlington Financial Advisors LLC

Arlington Financial Advisors LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 43,987 shares of the biopharmaceutical company’s stock after selling 2,552 shares during the quarter. Arlington Financial Advisors LLC’s holdings in Gilead Sciences were worth $4,877,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Southland Equity Partners LLC lifted its stake in shares of Gilead Sciences by 2.9% in the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $364,000 after acquiring an additional 92 shares in the last quarter. Twelve Points Wealth Management LLC lifted its stake in shares of Gilead Sciences by 1.5% in the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock worth $721,000 after acquiring an additional 98 shares in the last quarter. Argentarii LLC lifted its stake in shares of Gilead Sciences by 3.0% in the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock worth $380,000 after acquiring an additional 99 shares in the last quarter. Investment Research & Advisory Group Inc. lifted its stake in shares of Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 100 shares in the last quarter. Finally, Lodestar Private Asset Management LLC lifted its stake in shares of Gilead Sciences by 3.6% in the first quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company’s stock worth $318,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 66,000 shares of company stock valued at $7,632,100. 0.27% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

GILD has been the topic of several recent analyst reports. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Cantor Fitzgerald boosted their price target on Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Royal Bank Of Canada upped their price objective on Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 8th. Rothschild & Co Redburn upped their price objective on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Finally, Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a research note on Tuesday, August 19th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $118.08.

Gilead Sciences Stock Up 0.2%

NASDAQ:GILD opened at $118.48 on Wednesday. The firm has a market capitalization of $147.01 billion, a PE ratio of 23.60, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The stock has a 50 day moving average of $114.84 and a 200-day moving average of $110.35. Gilead Sciences, Inc. has a 52 week low of $84.80 and a 52 week high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio is 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.